Charles River Laboratories (CRL) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $2.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.51%. A quarter ago, it was expected that this medical research equipment and services provider would post earnings of $2.32 per share when it actually produced earnings of $2.43, delivering a surprise ...

Charles River Laboratories 4Q 2025 Results & 2026 Guidance February 18, 2026 Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends o ...

Charles River forecasts upbeat 2026 profit on improved demand for drug development services | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]- Companies[Charles River Laboratories International Inc]FollowFeb 18 (Reuters) - Contract drug developer Charles River Laboratories [(CRL.N), opens new tab] on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug discovery and developme ...

Revenue Performance - Fourth-quarter revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million in Q4 2024[1] - Full-year revenue for 2025 was $4.02 billion, down 0.9% from $4.05 billion in 2024, with a 1.6% decline on an organic basis[13] - Total revenue for the three months ended December 27, 2025, was $994.2 million, a decrease of 0.3% compared to $1,002.5 million for the same period in 2024[32] - Service revenue for the twelve months ended December 27, 2025, was $3.25 billion, down from $3.30 billion in 2024, reflecting a decline of approximately 1.6%[32] - Total revenue for the twelve months ended December 27, 2025, was $4,015.4 million, a slight decrease from $4,049.9 million in the previous year[37] - Total revenue growth for the three months ended December 27, 2025, reported a decline of 0.8%[43] - For the twelve months ended December 27, 2025, total revenue growth was down 0.9%, with the RMS Segment growing by 2.0%[43] Segment Performance - The DSA segment revenue was $591.6 million in Q4 2025, a decrease of 2.0% from $603.3 million in Q4 2024[8] - The Manufacturing segment revenue was $196.4 million in Q4 2025, an increase of 0.7% from $194.9 million in Q4 2024[11] - The RMS segment revenue for 2025 was $846.1 million, an increase of 2.0% from $829.4 million in 2024[16] - RMS Segment revenue grew by 1.0% for the same period, while DSA Segment and MS Segment reported declines of 2.0% and 0.4%, respectively[43] - The DSA Segment reported a 2.6% decline in non-GAAP organic revenue growth for the twelve months[43] Earnings and Losses - GAAP loss per share for Q4 2025 was $(5.62), compared to a loss of $(4.22) per share in Q4 2024[3] - Non-GAAP earnings per share for Q4 2025 were $2.39, a decrease of 10.2% from $2.66 in Q4 2024[4] - The company reported a net loss of $276.3 million for the three months ended December 27, 2025, compared to a net loss of $214.5 million for the same period in 2024[32] - Operating income (loss) for the three months ended December 27, 2025, was $(283.4) million, compared to $(167.7) million in the same period of 2024[32] - The net loss available to common shareholders for the three months ended December 27, 2025, was $(276.6) million, compared to $(215.7) million in the same period last year[41] Impairments and Charges - The company incurred an intangible asset impairment charge of $211.0 million for the three months ended December 27, 2025[32] - The company recognized a goodwill impairment charge of $165.0 million in fiscal year 2025, following a triggering event due to a loss of key customers[38] - Intangible asset impairment charges totaled $210.9 million, with $102.0 million related to the RMS Cell Solutions asset group and $108.9 million to the Manufacturing CDMO Gene Therapy asset group[38] - The company reported a goodwill impairment of $165,000 thousand for the twelve months ended December 27, 2025, compared to $215,000 thousand in the previous year[35] Future Expectations - The company expects organic revenue growth to return in the second half of 2026, driven by positive DSA booking trends[20] - Non-GAAP EPS for 2026 is projected to increase by approximately 4% to 9% due to cost savings and a lower tax rate[20] - The 2026 revenue guidance indicates growth of at least flat to +1.5%, with organic revenue expected to be (1.0)% to at least flat[22] - Future expectations include the impact of foreign exchange, interest rates, and enhanced efficiency initiatives on revenue growth[29] Financial Position - Total assets decreased to $7,135,422 thousand as of December 27, 2025, from $7,528,345 thousand as of December 28, 2024, representing a decline of approximately 5.2%[34] - Total current liabilities increased to $1,120,315 thousand as of December 27, 2025, from $994,101 thousand as of December 28, 2024, marking an increase of approximately 12.7%[34] - The total equity of Charles River Laboratories decreased to $3,169,931 thousand as of December 27, 2025, from $3,466,952 thousand as of December 28, 2024, a decline of approximately 8.6%[34] - Cash flows from operating activities provided $737,646 thousand for the twelve months ended December 27, 2025, slightly up from $734,577 thousand in 2024[35] - Cash, cash equivalents, and restricted cash at the end of the period increased to $215,997 thousand from $205,570 thousand, reflecting a net change of $10,427 thousand[35] Non-GAAP Measures - The company plans to continue assessing the potential value of reporting non-GAAP results to provide investors with a clearer understanding of core operating results[27] - The company emphasizes the importance of non-GAAP financial measures for understanding core operating results and future prospects[43] - Non-GAAP operating income as a percentage of revenue for the Research Models and Services segment was 21.9% for the three months ended December 27, 2025, down from 22.8% in the same period of 2024[36] - Non-GAAP operating income for the twelve months ended December 27, 2025, was $768.8 million, representing 19.8% of revenue, compared to 19.9% in the prior year[41] - Non-GAAP adjustments to operating income for the twelve months ended December 27, 2025, amounted to $764.1 million, up from $575.3 million in the previous year[41] - Non-GAAP operating income as a percentage of revenue for the three months ended December 27, 2025, was 32.1%, an increase from 28.7% in the prior year[37] Inventory and Supply Chain - The company incurred $27 million in inventory charges related to non-human primate supply chain issues in fiscal year 2024[38]

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Executive Appointments. ...

Markets have been volatile, with the S&P 500 ending 0.1 per cent higher on Tuesday after falling as much ‌as 0.9 per cent ⁠early in the ⁠session. The Nasdaq and the Dow also saw similar reversals. Wall Street's main indexes have been rocked this month by worries of disruption ​from rapidly improving AI tools that hit sectors from software to trucking.Broader AI-linked and megacap technology stocks had also lost ​ground as investors looked for stronger evidence the heavy investments in the technology were t ...

The upcoming report from Charles River Laboratories (CRL) is expected to reveal quarterly earnings of $2.33 per share, indicating a decline of 12.4% compared to the year-ago period. Analysts forecast revenues of $985.92 million, representing a decline of 1.7% year over year.The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timef ...

Core Insights - Charles River Laboratories International, Inc. (NYSE:CRL) is recognized as one of the top mid-cap AI stocks to invest in according to hedge funds, with a price target increase from $197 to $251 by TD Cowen, indicating a potential upside of 38.49% [1] - The firm anticipates solid quarterly results for Q4 and believes that the 2026 guidance could clarify operating conditions for investors [2] - A new gene therapy collaboration with Gazi University has been announced, focusing on advancing research for Hyperphosphatemic tumoral calcinosis (HTC) [3][4] Company Developments - The collaboration with Gazi University involves providing plasmid DNA for AAV production and support for in vitro efficacy studies, aimed at early-stage gene therapy programs [3][4] - Kerstin Dolph, Corporate Senior Vice President, emphasized the importance of this collaboration in transforming innovative concepts into real-world therapies [4] - Charles River Laboratories operates in various segments including Discovery and Safety Assessment, Research Models and Services, and Manufacturing Solutions, and has a global presence [4]

Core Insights - Charles River Laboratories International, Inc. (CRL) is set to report its fourth-quarter 2025 results on February 18, with adjusted earnings per share (EPS) of $2.43 in the last quarter exceeding the Zacks Consensus Estimate by 4.74% [1] Financial Estimates - The Zacks Consensus Estimate for CRL's revenues is $985.9 million, indicating a 1.7% decline from the previous year [2] - The Zacks Consensus Estimate for EPS is $2.33, reflecting a 12.4% year-over-year decrease [2] Performance and Trends - Earnings estimates have remained unchanged over the past 30 days, with a consistent performance noted in the previous quarters [3] - The RMS segment is expected to see a 0.5% revenue increase in Q4 2025, driven by large research model product revenues, particularly from Noveprim and GEMS [8] Collaborations and Revenue Drivers - CRL engaged in collaborations with Toxys and X-Chem, which may positively impact revenues through enhanced service offerings [4][5] - Despite NIH budget cuts, revenues from academic and government clients are anticipated to remain favorable, although early-stage biotech demand may be constrained by funding challenges [7] Segment Performance - The Discovery and Safety Assessment (DSA) segment is projected to experience a 3.9% revenue decline year-over-year due to budget pressures from biopharmaceutical clients [11] - The Manufacturing Solutions segment is expected to benefit from strong performance in the Microbial Solutions business, with a projected revenue increase of 2.3% year-over-year [12][14] Market Position and Outlook - CRL's overall pricing environment is expected to remain stable, but the DSA segment may face challenges impacting overall revenues [11] - The company has a Zacks Rank of 3, indicating a hold position, with an Earnings ESP of -0.46%, suggesting a lower likelihood of beating estimates [15]

Core Viewpoint - Charles River Laboratories International, Inc. is set to release its fourth-quarter and full-year 2025 financial results along with guidance for 2026 on February 18, before the market opens [1] Group 1 - A conference call to discuss the financial results and guidance will take place on February 18 at 8:30 a.m. ET [1] - Investors can access a live webcast of the conference call through the Investor Relations section of the company's website [2] - A replay of the conference call will also be available on the same website [2] Group 2 - Charles River Laboratories provides essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions globally [3] - The company focuses on accelerating research and drug development efforts for its clients [3] - Charles River's dedicated employees aim to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies [3]